在新冠肺炎中使用精神疗法——另一种抗炎症途径?

IF 0.3 Q4 PSYCHIATRY
J. Morillo, V. Morillo, Maria Angelica Marquina, Milagros Rojas, M. Nava
{"title":"在新冠肺炎中使用精神疗法——另一种抗炎症途径?","authors":"J. Morillo, V. Morillo, Maria Angelica Marquina, Milagros Rojas, M. Nava","doi":"10.2174/2666082218666220812114149","DOIUrl":null,"url":null,"abstract":"\n\nThe emergence of the novel coronavirus SARS-CoV-2 has had a significant impact on the population of the world, disrupting healthcare systems around the globe and leading to human and material losses. While different vaccines have been approved in record time, there continues to be a high number of daily new cases and patients face a wide range of presentations of the disease, from asymptomatic to potentially fatal. Therefore, the search for therapeutic agents that can aid in the management and control of the disease has become one of the main goals for researchers and clinicians. As an inflammatory disease, targets for the treatment of COVID-19 have largely involved the immune system. Inflammation has also been associated with mental health disorders, and studies have shown the potential involvement of inflammatory pathways in the pathophysiology of depression. As a consequence, the hypothesis of using antidepressants and other psychotropics for the treatment of COVID-19 has emerged. In this review, we aim to summarize the molecular pathways that could be involved as well as the emergent evidence that has been reported by studies performed since the appearance of SARS-CoV-2 in 2019. While it has been observed that there are potential therapeutic pathways for the use of antidepressants in the treatment of COVID-19, additional studies are needed to evaluate the feasibility, safety, and efficacy of psychotropics in this disease.\n","PeriodicalId":36711,"journal":{"name":"Current Psychiatry Research and Reviews","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2022-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Use Of Psychotropics In Covid-19 – Another Anti-Inflammatory Pathway?\",\"authors\":\"J. Morillo, V. Morillo, Maria Angelica Marquina, Milagros Rojas, M. Nava\",\"doi\":\"10.2174/2666082218666220812114149\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nThe emergence of the novel coronavirus SARS-CoV-2 has had a significant impact on the population of the world, disrupting healthcare systems around the globe and leading to human and material losses. While different vaccines have been approved in record time, there continues to be a high number of daily new cases and patients face a wide range of presentations of the disease, from asymptomatic to potentially fatal. Therefore, the search for therapeutic agents that can aid in the management and control of the disease has become one of the main goals for researchers and clinicians. As an inflammatory disease, targets for the treatment of COVID-19 have largely involved the immune system. Inflammation has also been associated with mental health disorders, and studies have shown the potential involvement of inflammatory pathways in the pathophysiology of depression. As a consequence, the hypothesis of using antidepressants and other psychotropics for the treatment of COVID-19 has emerged. In this review, we aim to summarize the molecular pathways that could be involved as well as the emergent evidence that has been reported by studies performed since the appearance of SARS-CoV-2 in 2019. While it has been observed that there are potential therapeutic pathways for the use of antidepressants in the treatment of COVID-19, additional studies are needed to evaluate the feasibility, safety, and efficacy of psychotropics in this disease.\\n\",\"PeriodicalId\":36711,\"journal\":{\"name\":\"Current Psychiatry Research and Reviews\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2022-08-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Psychiatry Research and Reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/2666082218666220812114149\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Psychiatry Research and Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2666082218666220812114149","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

摘要

新型冠状病毒SARS-CoV-2的出现对世界人口产生了重大影响,扰乱了全球医疗系统,并导致人员和物质损失。尽管不同的疫苗在创纪录的时间内获得批准,但每天仍有大量新增病例,患者面临着从无症状到潜在致命的各种疾病表现。因此,寻找有助于疾病管理和控制的治疗剂已成为研究人员和临床医生的主要目标之一。作为一种炎症性疾病,新冠肺炎的治疗靶点在很大程度上涉及免疫系统。炎症也与心理健康障碍有关,研究表明炎症途径可能参与抑郁症的病理生理学。因此,出现了使用抗抑郁药和其他精神药物治疗新冠肺炎的假说。在这篇综述中,我们旨在总结可能涉及的分子途径,以及自2019年严重急性呼吸系统综合征冠状病毒2型出现以来进行的研究报告的新证据。虽然已经观察到抗抑郁药在治疗新冠肺炎中有潜在的治疗途径,但还需要进一步的研究来评估精神药物在该疾病中的可行性、安全性和疗效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Use Of Psychotropics In Covid-19 – Another Anti-Inflammatory Pathway?
The emergence of the novel coronavirus SARS-CoV-2 has had a significant impact on the population of the world, disrupting healthcare systems around the globe and leading to human and material losses. While different vaccines have been approved in record time, there continues to be a high number of daily new cases and patients face a wide range of presentations of the disease, from asymptomatic to potentially fatal. Therefore, the search for therapeutic agents that can aid in the management and control of the disease has become one of the main goals for researchers and clinicians. As an inflammatory disease, targets for the treatment of COVID-19 have largely involved the immune system. Inflammation has also been associated with mental health disorders, and studies have shown the potential involvement of inflammatory pathways in the pathophysiology of depression. As a consequence, the hypothesis of using antidepressants and other psychotropics for the treatment of COVID-19 has emerged. In this review, we aim to summarize the molecular pathways that could be involved as well as the emergent evidence that has been reported by studies performed since the appearance of SARS-CoV-2 in 2019. While it has been observed that there are potential therapeutic pathways for the use of antidepressants in the treatment of COVID-19, additional studies are needed to evaluate the feasibility, safety, and efficacy of psychotropics in this disease.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Psychiatry Research and Reviews
Current Psychiatry Research and Reviews Medicine-Psychiatry and Mental Health
CiteScore
0.60
自引率
0.00%
发文量
51
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信